Sean Lavin
BTIG Research
Recent Quotes
"We see about 20% upside in ISRG over the next year."
—
Sean Lavin, Lazard Capital Markets
(1/14/13)
more >
"We expect ISRG's margins and earnings to expand long term."
—
Sean Lavin, Lazard Capital Markets
(12/20/12)
more >
"MDT is the most diversified medical device company in the world."
—
Sean Lavin, Lazard Capital Markets
(10/31/12)
more >
"Our rating of EW is Buy."
—
Sean Lavin, Lazard Capital Markets
(8/10/12)
more >
"We rate EW shares a Buy."
—
Sean Lavin, Lazard Capital Markets
(7/9/12)
more >
"ISRG's funnel in the U.S. remains immense."
—
Sean Lavin, BTIG Research
(5/25/12)
more >
"EW's Sapien 3 FIM data looks quite promising; our rating is Buy."
—
Sean Lavin, Lazard Capital Markets
(5/24/12)
more >
"MDT is the world's most diversified pure play medical device company."
—
Sean Lavin, Lazard Capital Markets
(4/30/12)
more >
